Astellas (TYO: 4503) is a Japanese pharma company focused on six key therapy areas: transplantation, urology, oncology, dermatology, anti-infectives, and pain management.
Astellas aims to improve the lives of patients with a number of other diseases, including diabetes and cardiovascular, CNS diseases, respiratory, and gastrointestinal.
Astellas produces Betmiga (mirabegron), a drug designed for the symptomatic treatment of urinary frequency, urgency and urge incontinence associated with overactive bladder.
In December 2013 Astellas announced the initiation of a Phase II trial of ASP0113 in 140 solid organ transplant (SOT) recipients. The study is designed to evaluate the safety and efficacy of ASP0113 compared to placebo as measured by the incidence of cytomegalovirus viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor.